arrow
C

Christopher L. D. McMillan

University of Queensland
H指数:17
被引数:1,094

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022)

疫苗诱导及混合免疫对澳大利亚昆士兰州两个队列中SARS-CoV-2关切变体的作用(2021-2022)

2025-10-130
PRE
A nanobody-based therapeutic targeting Nipah virus limits viral escape

靶向尼帕病毒的基于纳米抗体的治疗剂限制了病毒逃逸

2025-07-080
PRE
Twelfth scientific biennial meeting of the Australasian Virology Society: AVS12 2024

第十二届澳大拉西亚病毒学会科学双年会议:AVS12 2024

2025-05-200
OA
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
2022-12-3111
OAAI
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
2022-11-0189
OAAI
A platform technology for generating subunit vaccines against diverse viral pathogens

用于产生针对多种病毒病原体的亚单位疫苗的平台技术

2022-08-1811
OAAI
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants

用于检测不同SARS-CoV-2变体的核衣壳特异性诊断

2022-06-1013
OAAI
Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration

在接种CoronaVac疫苗之前,SARS-CoV-2感染或幼稚的个体中缺乏抗RBD抗体导致仅四个月的短暂保护

2022-04-284
OAAI
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine

通过单剂量皮肤贴片递送的SARS-CoV-2刺突疫苗提供完全保护

2021-10-2932
OAAI
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19

新型冠状病毒肺炎的SARS-CoV-2靶向siRNA纳米颗粒疗法

2021-07-0180
OAAI
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
2021-06-0887
OAAI